{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:17:47Z","timestamp":1787847467755,"version":"build-2784847793"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background and Objectives:<\/jats:title>\n                    <jats:p>In India, the uterine fibroid is a common indication of hysterectomy. An effective option for medical treatment may decrease the morbidity associated with hysterectomy. We aimed to evaluate the effect of mifepristone (25 mg), progesterone antagonist, on uterine fibroids in perimenopausal women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Fifty-four perimenopausal women of age \u226518 years having symptomatic uterine fibroids were selected from Gynecology OPD and given 25 mg mifepristone once daily continuously for 2\u20134 cycles of 3 months each. Variables such as baseline fibroid size, position, and hemoglobin were measured and followed at 3, 6, 9, and 12 months. The data were entered in MS EXCEL spreadsheet and analysis was done using Statistical Package for Social Sciences (SPSS) version 21.0. A\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value of &lt;0.05 was considered statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Majority were intramural fibroids (70.37%) followed by submucosal in 16.67%. Size of fibroids ranged from &lt;3 to &gt;7 cm; the majority of fibroids were in 5\u20137 cm size. No significant association of location with the size of fibroid was found. Out of 54 cases included in the study, change in size in uterine fibroids was observed in 98.14% cases. There was an increase in hemoglobin, from 8.6 g% at baseline to 9.7 g% at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Mifepristone resulted in a reduction in uterine fibroids size and an increase in hemoglobin at the end of 12 months. It may be an option for uterine leiomyoma treatment, as it is given orally, cost-effective and has minimal side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_467_20","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T10:08:40Z","timestamp":1595758120000},"page":"3230-3235","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A prospective interventional study to evaluate the effects of medical therapy (Mifepristone 25 mg) on the management of uterine fibroids"],"prefix":"10.4103","volume":"9","author":[{"given":"Meeta","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Acharaya Shri Chander College of Medical Sciences and Hospital (ASCOMS), Jammu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narita","family":"Jamwal","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Acharaya Shri Chander College of Medical Sciences and Hospital (ASCOMS), Jammu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Sabharwal","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Superspeciality Hospital, GMC, Jammu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Sobti","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Acharaya Shri Chander College of Medical Sciences and Hospital (ASCOMS), Jammu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7]]},"reference":[{"key":"R1-20260813","first-page":"877","article-title":"The conservative and interventional treatment of fibroids","volume":"111","author":"Boosz","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"R2-20260813","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ijgo.13102","article-title":"Epidemiology and management of uterine fibroids","volume":"149","author":"Giuliani","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"issue":"F1000 Faculty Rev","key":"R3-20260813","doi-asserted-by":"crossref","first-page":"183","DOI":"10.12688\/f1000research.6189.1","article-title":"Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management","volume":"4","author":"Taylor","year":"2015","journal-title":"F1000Res"},{"key":"R4-20260813","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.fertnstert.2013.08.039","article-title":"Effects of mifepristone on uterine leiomyoma in premenopausal women: A meta-analysis","volume":"100","author":"Shen","year":"2013","journal-title":"Fertil Steril"},{"key":"R5-20260813","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/IJWH.S51083","article-title":"Uterine fibroids: Current perspectives","volume":"6","author":"Khan","year":"2014","journal-title":"Int J Womens Health"},{"key":"R6-20260813","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/TCRM.S147318","article-title":"Uterine fibroids: An update on current and emerging medical treatment options","volume":"15","author":"Farris","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"R7-20260813","first-page":"118","article-title":"Role of mifepristone in conservative management of fibroid uterus","volume":"4","author":"Raghav","year":"2016","journal-title":"World J Pharm Sci"},{"key":"R8-20260813","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1097\/MD.0000000000006124","article-title":"Different dosages of mifepristone versus enantone to treat uterine fibroids: A multicenter randomized controlled trial","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R9-20260813","first-page":"1154","article-title":"Low dose mifepristone in medical management of uterine leiomyoma-an experience from a tertiary care hospital from north India","volume":"137","author":"Kulshrestha","year":"2013","journal-title":"Indian J Med Res"},{"key":"R10-20260813","first-page":"38","article-title":"Effects of low dose oral mifepristone on uterine fibroids","volume":"9","author":"Saxena","year":"2019","journal-title":"Indian Obs Gyn"},{"key":"R11-20260813","article-title":"Analysis of medication data of women with uterine fibroids based on data mining technology","author":"Xuan","year":"2019","journal-title":"J Inf Pub Health"},{"key":"R12-20260813","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: A randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R13-20260813","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0015-0282(16)57678-X","article-title":"Regression of uterine leiomyomata to the antiprogesterone RU 486 dose response effect","volume":"64","author":"Murphy","year":"1995","journal-title":"Fertil Steril"},{"key":"R14-20260813","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","article-title":"Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial","volume":"24","author":"Engman","year":"2009","journal-title":"Hum Reprod"},{"key":"R15-20260813","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/jmh.JMH_100_17","article-title":"Mifepristone therapy in symptomatic leiomyomata using a variable dose pattern with a favourable outcome","volume":"9","author":"Jain","year":"2018","journal-title":"J Mid-life Health"},{"key":"R16-20260813","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5468\/ogs.2018.61.2.192","article-title":"Current medical treatment of uterine fibroids","volume":"61","author":"Sohn","year":"2018","journal-title":"Obstet Gynecol Sci"},{"key":"R17-20260813","first-page":"22","article-title":"Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman","volume":"4","author":"Seth","year":"2013","journal-title":"J Midlife Health"},{"key":"R18-20260813","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0300-1652.86123","article-title":"A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri","volume":"52","author":"Mukherjee","year":"2011","journal-title":"Niger Med J"},{"key":"R19-20260813","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bpobgyn.2008.03.001","article-title":"Medical management of fibroids","volume":"22","author":"Sankaran","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R20-20260813","first-page":"10816","article-title":"Effect of mifepristone combined with interventional embolization on patients with uterine fibroids","volume":"12","author":"Wang","year":"2019","journal-title":"Int J Clin Exp Med"},{"key":"R21-20260813","first-page":"100","article-title":"Uterine fibroids: Diagnosis and treatment","volume":"95","author":"De La Cruz","year":"2017","journal-title":"Am Fam Physician"},{"key":"R22-20260813","first-page":"791248","article-title":"Complications of uterine fibroids and their management, surgical management of fibroids, laparoscopy and hysteroscopy versus hysterectomy, haemorrhage, adhesions, and complications","author":"Mettler","year":"2012","journal-title":"Obstet Gynecol Int 2012"},{"key":"R23-20260813","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/jog.14002","article-title":"Uterine fibroid management: Today and tomorrow","volume":"45","author":"Dolmans","year":"2019","journal-title":"J Obstet Gynaecol Res"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_467_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:19:17Z","timestamp":1787843957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_467_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_467_20","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"2020-03-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}